InnoSer is acquiring a variety of preclinical imaging modalities for its Diepenbeek facility to offer its customers a comprehensive assessment of their models and compounds. Non-invasive and high-throughput kinetic assays with real-time readouts will improve screening efficiency and success rates. With additions expected in the near future, two initial modalities we provide are as below.
Ultrasound and photoacoustic imaging
InnoSer recently added a Visual Sonic’s Vevo 3100 to its imaging capabilities. Vevo 3100 combines high-resolution images with high frame-rates and advanced image processing. It also preserves and enhances image acquisition, whilst reducing noise and artifacts.
Ultrasound and photoacoustic imaging are ideal tools for quickly collecting anatomical, hemodynamic, functional, and molecular data in small animals. This makes them extremely useful for (immuno-) oncology applications, where volumetric analyses and the assessment of vascularization/perfusion allow tracking the tumor’s progression, even in pre-palpable lesions.
Also, tracking of fluids and fluid-dynamics in the context of InnoSer’s autosomal dominant polycystic kidney disease (ADPKD) screening platform could be hugely beneficial. Here, in vivo imaging may be especially useful for monitoring studies with a very long duration, such as the p40 and p40long studies, from which the latter may take over a year to complete. By using ultrasound we may quickly determine whether a compound shows efficacy. This allows us to terminate the study at an early stage, saving our customer’s valuable time and resources. By reducing the risks associated with the outsourcing of these long projects we make these, lifelike, models an even more attractive option.
Fluorescence and bioluminescence imaging
InnoSer also introduces the IVIS Spectrum that will provide high sensitivity, high throughput, and high-resolution in vivo fluorescence and bioluminescence imaging (BLI) By using 3D optical tomography, InnoSer will be able to offer monitoring of disease progression, cell trafficking and gene expression patterns in living animals. This can be especially useful for tracking tumorigenicity and tumor progression in mice inoculated with luciferase positive tumor cells. Also, it is a valuable tool for localizing and tracking cancer metastasis.
InnoSer aims to expand its imaging capabilities with Positron Emission Tomography (PET), as well as and high throughput in vitro imaging modalities in the near future.